9 November 2026 · Updated November 2026 · 12 min read

Exosomes After Laser: CO2, Halo, Moxi, Fraxel and Clear + Brilliant Compared

Exosomes after laser, device by device: ablative versus non-ablative channels, the fractional CO2 split-face trial, and what practices document.

ExosomesFractional CO2Hybrid Fractional LaserNon-Ablative Fractional Laser1927 nm ThuliumLaser-Assisted DeliveryPractice Documentation
BB
Cited sources

Whether exosome material follows a laser session is the practitioner’s decision, and the published record on that question is organized by device class rather than by brand. Ablative fractional lasers leave open columns that close progressively over the first day [3, 4], while non-ablative fractional lasers leave coagulated columns under a surface that stays largely intact at lower settings [15], so the window, the expected uptake and the depth of the evidence all differ by class.

This guide compares five devices practices ask about by name: Fraxel re:pair and Fraxel DUAL, Halo, Moxi and Clear + Brilliant. The names are trademarks of their owners and are used only to identify the devices. For each class it sets out the wavelength, the channel it leaves, the studies of vesicle material after that class, and what a practice can document.

25
adults in the 2020 double-blind, randomized split-face trial that applied exosome gel after each of three fractional CO2 sessions (Kwon 2020)
24 hours
period over which Banzhaf and colleagues imaged fractional CO2 channels closing in six volunteers in 2016
16
facial vesicle studies in a 2026 systematic review that rated certainty low or very low (Gaebe 2026)

Regulatory position

The FDA stated in its 2019 public safety notification, still posted as of 9 November 2026, that there are currently no FDA-approved exosome products [19]. The 510(k) records for the Fraxel and Clear + Brilliant systems list them under 21 CFR 878.4810, the regulation for laser surgical instruments used in general and plastic surgery and in dermatology, and laser products carry the performance standard at 21 CFR 1040.10 [20]. The Fraxel re:pair and Clear + Brilliant clearance summaries reviewed for this guide describe the lasers themselves with no mention of applying a topical product [20]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and device settings, timing and patient selection are practitioner decisions this guide does not make.

Understanding why ablative and non-ablative lasers set different windows

An ablative fractional laser vaporizes narrow columns of tissue and leaves an open channel ringed by coagulation. Banzhaf and colleagues imaged 10,600 nm fractional CO2 channels in six volunteers in 2016 and reported that at a low energy 87 percent were open at one hour, 27 percent at 12 hours and 20 percent at 24 hours, while at a higher energy the figures were 100, 53 and 40 percent [3].

The 2940 nm erbium wavelength closes on a similar scale. Lee WR and colleagues reported in 2026 that water-loss measurements indicated channel closure within about 36 hours after a fractional Er:YAG laser in their preclinical model, and that lipid carriers of 76 to 81 nanometers, close to the size of small vesicles, were distributed mainly into the channels and then into the surrounding dermis [4].

A non-ablative fractional laser heats columns of tissue without removing them. Erlich and colleagues reviewed 27 studies of 1540 to 1570 nm lasers in 2026 and described a fluence-dependent continuum, with lower fluences preserving the stratum corneum and higher fluences producing subepidermal clefting in a semi-ablative pattern [15].

The 1927 nm thulium wavelength sits between the two. Wenande and colleagues imaged 1927 nm exposures in human skin in 2025 and reported effects generally limited to the epidermis under a residual stratum corneum at 3 mJ, with wider zones and ablation into the superficial dermis at 15 to 20 mJ, so the same wavelength can behave as non-ablative or ablative depending on the setting and the laser tip [12].

Why the timing question has no single answer

The closure data come from small molecules, nanocarriers and imaging, and no located human study has measured how deep vesicles travel after any of the devices in this guide. The Labadie 2022 guidelines on laser-assisted delivery recommended settings that give a channel wider than the delivered molecule [17], a principle that matters for particles the size of small vesicles and one a practice can weigh when it reads a device’s spot size and energy.

Comparing the five devices by class, wavelength and channel

The table places each named device in its class and lists the vesicle studies located for that class. Wavelengths come from the FDA 510(k) records or from peer-reviewed papers that name the device, and each cell carries its reference.

DeviceClassWavelengthAblativeChannel left behindVesicle studies located for the class
Fraxel re:pairAblative fractional CO2CO2 laser source (510(k) K080915) [20]; 10,600 nm in the CO2 studies cited [1, 3]YesOpen vaporized column with a coagulation rim; 20 to 40 percent still open at 24 hours in Banzhaf 2016 [3]Kwon 2020, Helmi 2026 and Abdel-Maguid 2021 [1, 5, 6]; Kwon 2020 used a CO2 laser of another maker
HaloHybrid fractional1470 nm plus 2940 nm in one pass [9, 10]PartlyShallow ablated microchannels (about 20 to 110 micrometers) over deeper coagulation columns (up to 700 micrometers) [9, 10]None located; Er:YAG closure data in Lee WR 2026 [4]
Fraxel DUALNon-ablative fractional1550 nm erbium glass and 1927 nm thulium (510(k) K130193) [14, 20]No at usual settingsCoagulation columns under a largely intact stratum corneum at lower settings [15]Wang T 2023 with a 1565 nm laser of another maker [7]
MoxiNon-ablative fractional1927 nm thulium [11]No at usual settingsSuperficial epidermal microthermal zones at low energy [12]None located
Clear + BrilliantLow-powered non-ablative fractional diode1440 nm and 1927 nm handpieces (510(k) K223647) [13, 20]NoShallow microthermal zones, 40 to 60 (1440 nm) or 20 to 40 (1927 nm) per square centimeter per pass [20]None located

Sirmans and colleagues named the hybrid device and its two wavelengths in a 2025 review of 169 facelift patients [9], and Waibel and colleagues described its 1470 nm coagulation to 700 micrometers and its 2940 nm ablation to 110 micrometers in 2018 [10]. Vingan and colleagues identified the fractionated, non-ablative 1927 nm thulium device by name in a 2023 prospective study [11], and Friedman and colleagues described the 1440 nm and 1927 nm diode system in a 2020 review [13].

Practices increasingly stack these classes in one visit. Kim and colleagues reported a 2026 pilot in 15 adults that combined intense pulsed light, the hybrid 1470/2940 nm laser and the fractionated 1927 nm laser in one or two sessions, with mild and transient symptoms and no serious adverse events [16], which means the channel a material meets can come from more than one row of the table.

The fractional CO2 split-face trial measured scars, erythema and downtime

Kwon and colleagues ran a 12-week, double-blind, randomized split-face trial in 25 Korean adults in 2020, with three sessions of a 10,600 nm fractional CO2 laser at a reported depth of about 1,100 to 1,400 micrometers [1]. One side of each face received an adipose stem cell exosome gel and the other a control gel, applied just after each session and then twice a day for two days at a lower concentration [1].

The primary endpoint was the percentage change in total score on the ECCA acne scar grading scale at the final visit. The trial reported a greater reduction on the exosome side, 32.5 against 19.9 percent, along with milder erythema in daily patient-recorded scores for a week after each session and shorter patient-reported downtime [1].

The paper also documented its material in detail. The authors characterized the vesicles by nanoparticle tracking, cryo-electron microscopy and the CD9, CD63 and CD81 surface markers, and the exosome and control solutions were manufactured and provided by the gel’s manufacturer, a disclosure the references carry [1].

Two other fractional CO2 studies sit beside it. Helmi and colleagues randomized 100 adults in 2026 to fractional CO2 alone or with exosome-mimetic nanovesicles and polynucleotide and reported 47.3 against 35.9 percent scar score reduction [6]. Abdel-Maguid and colleagues reported in 2021 that, in the 17-patient group of a 33-patient split-face trial, topical stem cell conditioned medium after fractional CO2 showed no significant clinical difference from the laser with saline [5].

Evidence after non-ablative lasers is thinner and comes from neighboring devices

The closest data for the 1550 nm class come from Wang T and colleagues in 2023. In an animal model, dye-labeled umbilical cord stem cell exosomes reached the deep dermis after a 1565 nm non-ablative fractional laser, and in a four-arm clinical comparison of 60 patients the group receiving that laser with exosomes showed significantly greater improvement than the group receiving the laser with saline, as the authors reported [7].

Park JY and Park JH randomized 75 adults in 2026 to a 1064 nm non-ablative fractional Nd:YAG laser alone or with human-derived or plant-derived exosome products over five sessions, and reported numerically greater short-term gains in both product arms with no serious adverse events [8]. That wavelength differs from the devices in the table, so the study shows the non-ablative design in use without speaking for any named device.

For low-powered 1440 nm and 1927 nm diode lasers, Friedman and colleagues stated in their 2020 review that the system facilitates delivery of small molecular-weight compounds such as L-ascorbic acid without compromising the barrier function of the stratum corneum [13]. Small molecules are far smaller than vesicles, so that finding marks a direction for research and leaves vesicle uptake after these devices unmeasured.

Skin type and settings change the risk picture for each class

Goldman and colleagues reviewed 15 clinical studies of the 1550 nm and 1927 nm wavelengths of the dual system in Fitzpatrick types III to VI in 2026 and reported that post-inflammatory hyperpigmentation rates varied, with lower rates where studies compared reduced energy or density [14]. Helmi and colleagues counted post-inflammatory hyperpigmentation as a secondary endpoint after fractional CO2 [6], which gives future combination studies a model to follow.

Fitzpatrick type, energy, density and number of passes therefore belong in the record alongside the material. A study that reports those fields lets a reader judge whether its results could apply to a different device or a different patient population.

Understanding what the evidence does not yet show

The combination literature is early, and its gaps are specific enough to list. Each one is also a design choice the next study can improve on.

  • No located published study pairs vesicle material with a hybrid 1470/2940 nm laser, a 1927 nm thulium laser or a low-powered 1440 nm diode laser, and none names any of the five devices in this guide.
  • No human study has measured vesicle depth after a laser session; Wang T 2023 tracked dye-labeled vesicles in animals [7], and MISEV2023 cautions that lipophilic dyes can transfer without the vesicle and give false-positive signals [18].
  • Samples are small: the fractional CO2 studies enrolled 25 to 100 participants [1, 5, 6], and Gaebe and colleagues rated the certainty of the facial vesicle evidence low or very low in a 2026 systematic review of 16 studies [2].
  • Materials differ by source, isolation and concentration, so a result for one product may not transfer to another; Helmi 2026 combined nanovesicles with polynucleotide, which mixes two variables [6].
  • Industry ties appear in the record: the Kwon 2020 solutions came from their manufacturer [1], and several authors of the dual-laser review in skin of color advise the laser’s maker or work for its parent company [14].
  • Follow-up is short, mostly 12 weeks to 3 months [1, 5, 6], and Goldman 2026 called for more data in Fitzpatrick type VI [14].

Documenting a laser and exosome session in practice

A practice that records the fields the published studies report can compare its own results with the literature and answer an investigator’s or a regulator’s questions from one file. The list below follows the studies and the MISEV2023 reporting headings cited in this guide [1, 18].

  • The device by model and 510(k) number, with wavelength, energy, density, spot size and number of passes
  • The device class and the channel it leaves, read against the comparison table above
  • The time from the end of the laser session to surface application of any material
  • The material by name and class: exosomes, exosome-mimetic nanovesicles, conditioned medium or another preparation
  • The lot number, expiry, certificate of analysis and characterization panel, mapped where possible to MISEV2023 headings [18]
  • The cold-chain record from receipt to use, and the time between thawing or reconstitution and application
  • Fitzpatrick type and pigmentary history
  • Recovery endpoints: erythema, edema, crusting, patient-reported downtime and photographs at fixed intervals
  • Any adverse event, with the lot number, and its report to the FDA through MedWatch [19]

Questions to ask a supplier

Which source cells and isolation method produced this lot? Does the certificate of analysis report particle size, concentration, positive and negative markers and sterility? How is the material shipped and at what temperature, and does the record cover every leg? Which published study, if any, used the same material?

Documentation carries the device evidence forward

The device-by-device picture is still being drawn, and new studies will fill in the rows that are empty today. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats; it ships frozen from the manufacturing facility, each vial carries its lot number, and a certificate of analysis is generated for every lot and available on request with the characterization panel and cold-chain records, so a practice can document every session to the standard the best studies set.

Practices that keep that record are well placed to add to the evidence as it grows. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice that wants to carry exosome material can apply for a verified account today.

Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

References

  1. 1.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized split-face trial over 12 weeks; 25 Korean adults with atrophic acne scars, Fitzpatrick III to IV; three sessions of a 10,600 nm fractional CO2 laser (a different maker from any device named in this article) at a reported depth of about 1,100 to 1,400 micrometers. Carries in this article: the gel was applied just after each session and twice a day for two days at a lower concentration; the trial reported 32.5 against 19.9 percent reduction in total ECCA scar score, milder erythema in daily patient-recorded scores and shorter patient-reported downtime, with the vesicles characterized by nanoparticle tracking, cryo-electron microscopy and CD9, CD63 and CD81 markers. Disclosure: the acknowledgements state that the exosome and control solutions were manufactured, purified and provided by the material’s manufacturer; the authors declared no conflicts.
  2. 2.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk of bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the review reported that most studies found improvement in at least one skin quality outcome and no serious adverse events, with risk of bias moderate to critical and GRADE certainty low or very low. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
  3. 3.Banzhaf CA, Wind BS, Mogensen M, Meesters AA, Paasch U, Wolkerstorfer A, et al. Spatiotemporal closure of fractional laser-ablated channels imaged by optical coherence tomography and reflectance confocal microscopy. Lasers Surg Med. 2016;48(2):157-65. PMID 26266688. doi:10.1002/lsm.22386In vivo imaging study (OCT and reflectance confocal microscopy) after 10,600 nm fractional CO2 at 5, 15 and 25 mJ per microbeam on the inner forearm of healthy volunteers; n = 6. Carries in this article: the authors reported 87, 27 and 20 percent of channels open at 1, 12 and 24 hours at 5 mJ, and 100, 53 and 40 percent at 25 mJ, with re-epithelialization from day 2. Disclosure: academic authors; no COI statement in the PubMed record.
  4. 4.Lee WR, Alalaiwe A, Tsai MT, Hu S, Chang FH, Chien MY, et al. Fractional microporation-guided delivery of nanoencapsulated drugs for enhanced cutaneous and follicular absorption: a comparison of ablative laser and radiofrequency microneedling. Drug Deliv Transl Res. 2026;16(1):248-267. PMID 40439860. doi:10.1007/s13346-025-01885-xPreclinical study (porcine skin permeation plus a mouse model) comparing fractional Er:YAG laser, the 2940 nm wavelength, with RF microneedling. Carries in this article: the authors reported channel closure within about 36 hours after the laser by water-loss measurement, and that lipid nanocarriers of 76 to 81 nanometers, close to small-vesicle size, sat mainly in the channels and were delivered less efficiently than free drug. Disclosure: the authors declared no competing interests.
  5. 5.Abdel-Maguid EM, Awad SM, Hassan YS, El-Mokhtar MA, El-Deek HE, Mekkawy MM. Efficacy of stem cell-conditioned medium vs. platelet-rich plasma as an adjuvant to ablative fractional CO2 laser resurfacing for atrophic post-acne scars: a split-face clinical trial. J Dermatolog Treat. 2021;32(2):242-249. PMID 31180258. doi:10.1080/09546634.2019.1630701Randomized split-face clinical trial in two groups, three monthly sessions, final assessment 3 months later, with biopsies; patients with atrophic post-acne scars (Egypt); n = 33 (group I, n = 17: conditioned medium against saline; group II, n = 16: PRP against conditioned medium). Carries in this article: the null result; in group I the authors reported no significant clinical difference between the fractional CO2 with stem cell conditioned medium side and the fractional CO2 only side (p = .63), while dermal collagen rose in both adjunct arms. Disclosure: academic authors; no COI statement in the PubMed record.
  6. 6.Helmi RR, Mohammed RSH, Nori W. Fractional CO2 laser augmented by polynucleotide and exosome-mimetic nanovesicles in atrophic acne scars: randomised comparative trial. Postepy Dermatol Alergol. 2026;43(3):314-321. PMID 42621380. PMC13487574. doi:10.5114/ada.2026.161825Randomized comparative trial, parallel arms, three sessions, assessed 3 months after the last session; adults aged 18 to 45 with atrophic acne scars, Fitzpatrick III to IV (Iraq); n = 100. Carries in this article: the largest located parallel-arm study after fractional CO2; the authors reported 47.3 against 35.9 percent ECCA reduction and fewer cases of post-inflammatory hyperpigmentation, 10 against 24 percent. The adjunct combined nanovesicles with polynucleotide, so effects cannot be assigned to vesicles alone. Disclosure: the authors declared no conflict of interest.
  7. 7.Wang T, Gao H, Wang D, Zhang C, Hu K, Zhang H, et al. Stem cell-derived exosomes in the treatment of melasma and its percutaneous penetration. Lasers Surg Med. 2023;55(2):178-189. PMID 36573453. doi:10.1002/lsm.23628Two-part study: an animal penetration model with PKH67-labeled umbilical cord MSC exosomes after microneedles, a 1565 nm non-ablative fractional laser or a plasma device, and a four-arm clinical comparison in 60 patients with melasma (China), including the 1565 nm laser with saline against the same laser with exosomes. Carries in this article: the only located vesicle data for a non-ablative fractional laser in the 1550 nm class; the authors reported labeled vesicles in the deep dermis after all three pretreatments in the animal model, and significantly greater improvement in each exosome group than in the laser-with-saline group. Disclosure: no COI statement in the PubMed record.
  8. 8.Park JY, Park JH. Randomized Clinical Study of Laser-Assisted Delivery of Exosome Boosters for Postoperative Facial Scars and Facial Rejuvenation. Life (Basel). 2026;16(2):217. PMID 41752855. PMC12942482. doi:10.3390/life16020217Randomized controlled clinical study, three arms, five sessions at two-week intervals; adults aged 20 to 75 with postoperative facial scars (Korea); n = 75. Carries in this article: a 1064 nm non-ablative fractional Nd:YAG laser alone or with human-derived or plant-derived topical exosome products; the authors reported numerically greater short-term gains in either product arm and no serious adverse events. Disclosure: the authors declared no conflicts of interest.
  9. 9.Sirmans SJ, Akhter MF, Hernandez M, Chishom T, Woltjen N, Bieber S, et al. A Clinical Safety Assessment of Hybrid Fractional Laser Use at Increased Depths for Facial Skin Rejuvenation in Patients Undergoing Rhytidectomy. Aesthet Surg J Open Forum. 2025;7:ojaf114. PMID 41200268. PMC12586331. doi:10.1093/asjof/ojaf114Retrospective review, 2017 to 2022, of facelift patients with or without same-session hybrid fractional laser; n = 169. Carries in this article: the full text names the HALO hybrid fractional laser, delivering a non-ablative 1470 nm and an ablative 2940 nm Er:YAG wavelength in one pass, with reported ranges of 100 to 700 micrometers for the 1470 nm depth and 20 to 100 micrometers for the 2940 nm depth. Disclosure: one author lists consulting for the maker of the hybrid laser among other companies; no vesicle material was studied.
  10. 10.Waibel S, Pozner J, Robb C, Tanzi E. Hybrid Fractional Laser: A Multi-Center Trial on the Safety and Efficacy for Photorejuvenation. J Drugs Dermatol. 2018;17(11):1164-1168. PMID 30481954Open-label, prospective multicenter study, two sessions 4 to 6 weeks apart; women, Fitzpatrick I to IV; n = 34 enrolled, 29 completed. Carries in this article: the authors described the hybrid system as non-ablative coagulation at 1470 nm to dermal depths up to 700 micrometers and ablative vaporization at 2940 nm in the epidermis up to 110 micrometers. Disclosure: no COI statement in the PubMed record; no vesicle material was studied.
  11. 11.Vingan NR, Panton JA, Barillas J, Lazzarini A, Hoopman J, Kenkel JM, et al. Investigating the efficacy of a fractionated 1927 nm laser for diffuse dyspigmentation and actinic changes. Lasers Surg Med. 2023;55(4):344-358. PMID 36950878. doi:10.1002/lsm.23653Single-center, prospective, nonrandomized study, two sessions one month apart; women, Fitzpatrick I to IV; n = 27. Carries in this article: the authors identify the device as a fractionated, nonablative 1927 nm thulium laser (MOXI) and report the session settings (15 mJ, 15 percent density, six passes) and no serious adverse events. Disclosure: academic authors (UT Southwestern); no vesicle material was studied.
  12. 12.Wenande E, Jacobsen K, Grove GL, Paasch U, Haedersdal M. Imaging 1927 nm Fractional Thulium Laser-Tissue Interactions: A Spectrum of Nonablative to Ablative Effects. J Cosmet Dermatol. 2025;24(7):e70304. PMID 40665805. PMC12264580. doi:10.1111/jocd.70304In vivo human imaging study (OCT and line-field confocal OCT) of 1927 nm fractional thulium exposures at 0, 3, 15 and 20 mJ on forearm skin. Carries in this article: the authors reported effects generally limited to the epidermis under a residual stratum corneum at 3 mJ, and wider zones with stratum corneum involvement and ablation into the superficial dermis at 15 to 20 mJ, so a 1927 nm device can sit anywhere from non-ablative to ablative by setting. Disclosure: one author received the study’s laser equipment from a device maker; other author disclosures unrelated to the work are listed in the record.
  13. 13.Friedman PM, Polder KD, Sodha P, Geronemus RG. The 1440 nm and 1927 nm Nonablative Fractional Diode Laser: Current Trends and Future Directions. J Drugs Dermatol. 2020;19(8):s3-11. PMID 32804450Narrative review in a journal supplement on the low-powered 1440 nm and 1927 nm nonablative fractional diode laser system. Carries in this article: the authors describe the two handpieces, water as the target chromophore, and reports that the system facilitates delivery of small molecular weight compounds such as L-ascorbic acid without compromising the stratum corneum barrier. Disclosure: a journal supplement; author disclosures are in the full text and were not available in the PubMed record.
  14. 14.Goldman MP, Wu DC, Khetarpal S, Jacobson A, Wang JV, Geronemus RG. Dual 1550-nm Erbium Glass Fiber and 1927-nm Thulium Fiber Non-ablative Fractional Laser System Treatment in Patients With Skin of Color: A Review of Clinical Studies and Unmet Needs. Lasers Surg Med. 2026;58(3):169-179. PMID 41668543. PMC12997386. doi:10.1002/lsm.70108Review of 15 clinical studies of the dual 1550 nm erbium glass and 1927 nm thulium non-ablative fractional system in Fitzpatrick III to VI. Carries in this article: the authors reported that post-inflammatory hyperpigmentation rates varied and that studies comparing settings reported lower rates with reduced energy or density, and that more data are needed for Fitzpatrick VI. Disclosure: one author is an employee of the laser maker’s parent company, and several authors advise, investigate or consult for the maker of the dual system.
  15. 15.Erlich G, Paasch U, Jacobsen K, Haedersdal M, Olesen UH. Repositioning Non-Ablative Fractional Lasers - Molecular and Histological Insights from a scoping review. J Dtsch Dermatol Ges. 2026. Published online ahead of print. PMID 42389967. doi:10.1111/ddg.70487Scoping review of 27 studies (10 molecular, 17 histological) of 1540 to 1570 nm non-ablative fractional lasers. Carries in this article: the authors described a fluence-dependent continuum in which lower fluences preserved the stratum corneum and higher fluences produced subepidermal clefting, a semi-ablative pattern. Disclosure: academic authors (Copenhagen, Leipzig); no COI statement in the PubMed record.
  16. 16.Kim C, Thota B, Nadarajan V, Barillas J, Hoopman JE, Kenkel JM. A Pilot Study Combining Intense Pulsed Light, Hybrid Fractional 1470/2940-nm Laser, and Fractionated 1927-nm Laser for Diffuse Pigmentation and Actinic Changes. Aesthet Surg J Open Forum. 2026;8:ojag172. doi:10.1093/asjof/ojag172Single-center, nonrandomized prospective pilot, one or two combined sessions; adults, Fitzpatrick I to IV; n = 15. Carries in this article: the hybrid 1470/2940 nm and fractionated 1927 nm classes are used together in the same session in current practice research, and the authors reported mild, transient symptoms and no serious adverse events. Disclosure: checked against the Crossref record (not yet indexed in PubMed, 9 November 2026); no vesicle material was studied.
  17. 17.Labadie JG, Ibrahim SA, Worley B, Kang BY, Rakita U, Rigali S, et al. Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery. JAMA Dermatol. 2022;158(10):1193-1201. PMID 35976634. doi:10.1001/jamadermatol.2022.3234Systematic review plus a two-round Delphi consensus; 54 studies of ablative and non-ablative fractional laser-assisted delivery. Carries in this article: the panel recommended settings that give a channel diameter greater than the delivered molecule; no recommendation addresses vesicle payloads. Disclosure: multi-author expert panel; individual disclosures are in the full text.
  18. 18.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline. Carries in this article: the reference headings (separation from non-vesicular particles, size, concentration, marker proteins, morphology) that a certificate of analysis can be read against, and the caution that lipophilic dyes can be exchanged without actual vesicle transfer, giving false-positive signals. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
  19. 19.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, with MedWatch named as the reporting route for adverse events.
  20. 20.U.S. Food and Drug Administration. 21 CFR 878.4810, Laser surgical instrument for use in general and plastic surgery and in dermatology (Class II), and 21 CFR 1040.10, Laser products (performance standard), verified 9 November 2026, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4810 and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1040.10; with 510(k) summaries K223647 (Clear + Brilliant Touch, 2022), K130193 (Fraxel DUAL 1550/1927, 2013) and K080915 (Fraxel re:pair, 2008), https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223647Federal regulations and 510(k) records (CDRH). Carries in this article: fractional lasers are classified as laser surgical instruments and carry the laser radiation performance standard; the K223647 summary lists 1440 nm and 1927 nm diode handpieces, describes the system as non-ablative and gives 40 to 60 (1440 nm) and 20 to 40 (1927 nm) microthermal zones per square centimeter per pass; the K080915 summary describes Fraxel re:pair as a CO2 laser source with delivery handpieces; the K130193 record lists the FRAXEL DUAL 1550/1927 Laser System; all three records list regulation 21 CFR 878.4810. The K223647 and K080915 summaries reviewed describe the lasers themselves and say nothing about applying a topical product.

Ask your practitioner how their exosomes are tested

Lab analysis shows what is in a lot: particle counts, vesicle markers, sterility and how the material was stored. A practice that sources carefully can answer these questions from its supplier’s records.

Frequently Asked Questions

Can you use exosomes after CO2 laser?
That is the practitioner’s decision, and the published studies show how it has been done. Kwon and colleagues applied an adipose stem cell exosome gel just after each of three fractional CO2 sessions in a 2020 double-blind split-face trial of 25 adults [1], and Banzhaf and colleagues reported in 2016 that most fractional CO2 channels had closed by 24 hours at both energies tested [3]. The FDA stated in 2019 that there are currently no FDA-approved exosome products [19].
Exosomes post laser: does ablative or non-ablative change the timing?
The device class changes what a material meets. Banzhaf and colleagues reported in 2016 that fractional CO2 channels close progressively over the first 24 hours [3], and Lee WR and colleagues reported closure within about 36 hours after a 2940 nm Er:YAG laser in a 2026 preclinical model [4]. Erlich and colleagues reported in 2026 that non-ablative 1540 to 1570 nm lasers at lower fluences preserve the stratum corneum, so no open channel forms [15].
What is known about exosomes after Halo laser?
Halo is a hybrid fractional laser that delivers a non-ablative 1470 nm and an ablative 2940 nm wavelength in one pass, as Sirmans and colleagues described in 2025 [9]. No located published study pairs a hybrid laser with vesicle material. The nearest data are the Er:YAG channel closure within about 36 hours reported by Lee WR and colleagues in 2026 [4] and the fractional CO2 vesicle trial by Kwon and colleagues in 2020 [1].
What is known about exosomes after Moxi?
Moxi is a fractionated, non-ablative 1927 nm thulium laser, as Vingan and colleagues identified it in a 2023 study [11]. No located published study pairs it with vesicle material. Wenande and colleagues reported in 2025 that 1927 nm exposures at low energy stay generally within the epidermis under a residual stratum corneum [12], which limits the channel available to a surface-applied material.
What is known about exosomes after Fraxel?
Fraxel is a family of lasers: Fraxel re:pair is a CO2 system (510(k) K080915) and Fraxel DUAL is a 1550 and 1927 nm system (510(k) K130193) [20]. No located study names either with vesicle material. The CO2 evidence comes from other CO2 devices, led by Kwon and colleagues in 2020 [1], and Wang T and colleagues reported vesicle data after a 1565 nm non-ablative laser in 2023 [7].
What is known about exosomes after Clear and Brilliant?
Clear + Brilliant is a low-powered non-ablative fractional diode laser with 1440 nm and 1927 nm handpieces, per FDA 510(k) K223647 [20]. No located published study pairs it with vesicle material. Friedman and colleagues stated in a 2020 review that the system facilitates delivery of small molecular-weight compounds such as L-ascorbic acid [13], which are far smaller than vesicles.
What did the fractional CO2 exosome split-face trial measure?
Kwon and colleagues measured the percentage change in total ECCA acne scar score at 12 weeks as the primary endpoint, with ECCA at earlier visits, subtype scores and investigator global assessment as secondary measures, while patients recorded erythema, edema, dryness and pain daily for a week after each session [1]. The 2020 trial reported a significantly greater reduction on the exosome side, with milder erythema and shorter downtime; the solutions were supplied by their manufacturer [1].
What should a practice document for exosomes after laser?
The device model, 510(k) number and settings, the time from the end of the session to application, the material’s lot number, certificate of analysis and characterization panel, the cold-chain record, Fitzpatrick type and recovery endpoints. The MISEV2023 guideline gives the characterization headings [18], and the FDA names MedWatch as the route for reporting adverse events [19].

ExaBlog Weekly for licensed practices

One email a week for licensed practices: new ExaBlog research reviews, practice guides and regulatory updates, each article citing its sources.

We write in English unless you check this box.

No spam. Unsubscribe any time.